- Home
- VTYX
as 07-11-2025 1:39pm EST
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 154.9M | IPO Year: | 2021 |
| Target Price: | $11.33 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.78 - $3.39 | Next Earning Date: | 08-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Ventyx Biosciences Inc. News
VTYX Breaking Stock News: Dive into VTYX Ticker-Specific Updates for Smart Investing
Simply Wall St.
17 days ago
Sight Sciences Leads The Pack Of 3 Promising Penny Stocks
Clinical Trials Arena
24 days ago
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s
MT Newswires
24 days ago
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires
25 days ago
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study
Simply Wall St.
25 days ago
Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m
GlobeNewswire
25 days ago
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease
GlobeNewswire
a month ago
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference
Simply Wall St.
2 months ago
Spotlight On 3 Penny Stocks With Market Caps Under $500M
Compare VTYX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTYX Ventyx Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.